{"id":68222,"date":"2026-06-15T21:49:10","date_gmt":"2026-06-15T13:49:10","guid":{"rendered":"https:\/\/flcube.com\/?p=68222"},"modified":"2026-06-15T21:49:12","modified_gmt":"2026-06-15T13:49:12","slug":"ssy-group-secures-exclusive-china-license-for-opt101-novel-peritoneal-dialysis-therapy-from-opterion-health","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68222","title":{"rendered":"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>SSY Group Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/2005:HKG\">HKG: 2005<\/a>)<\/strong> announced it has entered into a <strong>letter of intent<\/strong> with <strong>Switzerland-based Opterion Health AG<\/strong> for an <strong>exclusive license<\/strong> covering <strong>patents, know-how, and platform technology<\/strong> associated with <strong>OPT101<\/strong>, a <strong>Class 1 innovative drug<\/strong> for <strong>peritoneal dialysis<\/strong>. The agreement grants SSY rights to <strong>research, develop, manufacture, and commercialize OPT101 in mainland China until 2038<\/strong>, with a <strong>right of first refusal<\/strong> for <strong>Hong Kong, Taiwan, and Russia<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-licensing-agreement-details\" class=\"wp-block-heading\">Licensing Agreement Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Opterion Health AG (Switzerland)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>SSY Group Limited (HKG: 2005)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive license until 2038)<\/td><\/tr><tr><td><strong>Additional Rights<\/strong><\/td><td>Right of first refusal for Hong Kong, Taiwan, and Russia<\/td><\/tr><tr><td><strong>Technology Scope<\/strong><\/td><td>Patents, know-how, and platform technology for OPT101<\/td><\/tr><tr><td><strong>Development Rights<\/strong><\/td><td>Full research, development, manufacturing, and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-innovation\" class=\"wp-block-heading\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> OPT101 \u2013 novel non-glucose-based osmotic driver<\/li>\n\n\n\n<li><strong>Classification:<\/strong> Class 1 innovative drug (China regulatory classification)<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Peritoneal dialysis for end-stage renal disease<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Replaces traditional glucose-based osmotic drivers<\/li>\n\n\n\n<li><strong>Clinical Stage:<\/strong> Phase I trials ongoing in Europe<\/li>\n\n\n\n<li><strong>Data Timeline:<\/strong> Results expected Q3 2026<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-therapeutic-advantages-amp-market-need\" class=\"wp-block-heading\">Therapeutic Advantages &amp; Market Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Current Limitation<\/th><th>OPT101 Solution<\/th><\/tr><\/thead><tbody><tr><td><strong>Glucose-based complications<\/strong><\/td><td>Non-glucose osmotic driver eliminates metabolic side effects<\/td><\/tr><tr><td><strong>Metabolic disorders<\/strong><\/td><td>Reduced risk of hyperglycemia and insulin resistance<\/td><\/tr><tr><td><strong>Peritoneal membrane damage<\/strong><\/td><td>Potentially preserves peritoneal membrane integrity<\/td><\/tr><tr><td><strong>Long-term efficacy decline<\/strong><\/td><td>May maintain dialysis effectiveness over extended periods<\/td><\/tr><tr><td><strong>Patient quality of life<\/strong><\/td><td>Improved metabolic profile and reduced complications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-china-market-opportunity-analysis\" class=\"wp-block-heading\">China Market Opportunity Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ESRD Prevalence:<\/strong> Estimated 3-4 million end-stage renal disease patients in China<\/li>\n\n\n\n<li><strong>Peritoneal Dialysis Adoption:<\/strong> Growing preference due to home-based treatment advantages<\/li>\n\n\n\n<li><strong>Current Market:<\/strong> Dominated by glucose-based solutions with known long-term limitations<\/li>\n\n\n\n<li><strong>Regulatory Incentives:<\/strong> Class 1 innovative drugs receive priority review and market exclusivity<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Premium pricing opportunity for superior safety and efficacy profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-structure\" class=\"wp-block-heading\">Strategic Partnership Structure<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>letter of intent<\/strong> establishes a comprehensive licensing framework that positions SSY as the <strong>exclusive Chinese developer and commercializer<\/strong> of OPT101. The <strong>right of first refusal<\/strong> for additional territories provides strategic optionality for future expansion while maintaining focus on the core China market.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-differentiation\" class=\"wp-block-heading\">Competitive Landscape &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Gap:<\/strong> No non-glucose osmotic agents currently approved for peritoneal dialysis in China<\/li>\n\n\n\n<li><strong>First-Mover Advantage:<\/strong> Potential to establish new standard of care if clinical data supports superiority<\/li>\n\n\n\n<li><strong>Technology Barrier:<\/strong> Proprietary platform technology creates sustainable competitive advantage<\/li>\n\n\n\n<li><strong>Global Context:<\/strong> Part of broader industry shift toward improved peritoneal dialysis solutions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Q3 2026:<\/strong> Phase I data readout from European trials<\/li>\n\n\n\n<li><strong>2027:<\/strong> Potential NMPA clinical trial application submission<\/li>\n\n\n\n<li><strong>2028-2029:<\/strong> Phase II\/III clinical development in China<\/li>\n\n\n\n<li><strong>2030+:<\/strong> Potential commercial launch pending successful development<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> SSY to establish GMP-compliant production capabilities<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-strategic-implications\" class=\"wp-block-heading\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This partnership represents a significant strategic move for SSY to enter the <strong>specialty nephrology market<\/strong> with a potentially transformative therapy. The <strong>22-year exclusive license<\/strong> (until 2038) provides substantial commercial runway, while the <strong>Class 1 innovative drug status<\/strong> ensures regulatory advantages and market protection in China.<\/p>\n\n\n\n<h2 id=\"h-risk-considerations\" class=\"wp-block-heading\">Risk Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development Risk:<\/strong> Phase I data pending; later-stage trials may reveal unforeseen challenges<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> NMPA requirements for foreign-developed innovative drugs<\/li>\n\n\n\n<li><strong>Manufacturing Complexity:<\/strong> Technical challenges in producing novel osmotic agents at scale<\/li>\n\n\n\n<li><strong>Market Adoption:<\/strong> Physician and patient acceptance of new peritoneal dialysis paradigm<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, clinical development, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500084_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061500084_c.\"><\/object><a id=\"wp-block-file--media-8e4c88cb-1156-4127-a131-92f75acdbde8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500084_c.pdf\">2026061500084_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500084_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8e4c88cb-1156-4127-a131-92f75acdbde8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[2479,4798,2480],"class_list":["post-68222","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2005","tag-opterion-health","tag-ssy-group"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with Switzerland-based Opterion Health AG for an exclusive license covering patents, know-how, and platform technology associated with OPT101, a Class 1 innovative drug for peritoneal dialysis. The agreement grants SSY rights to research, develop, manufacture, and commercialize OPT101 in mainland China until 2038, with a right of first refusal for Hong Kong, Taiwan, and Russia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68222\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health\" \/>\n<meta property=\"og:description\" content=\"SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with Switzerland-based Opterion Health AG for an exclusive license covering patents, know-how, and platform technology associated with OPT101, a Class 1 innovative drug for peritoneal dialysis. The agreement grants SSY rights to research, develop, manufacture, and commercialize OPT101 in mainland China until 2038, with a right of first refusal for Hong Kong, Taiwan, and Russia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68222\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:49:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:49:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68222#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68222\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health\",\"datePublished\":\"2026-06-15T13:49:10+00:00\",\"dateModified\":\"2026-06-15T13:49:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68222\"},\"wordCount\":555,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2005\",\"Opterion Health\",\"SSY Group\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68222#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68222\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68222\",\"name\":\"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-15T13:49:10+00:00\",\"dateModified\":\"2026-06-15T13:49:12+00:00\",\"description\":\"SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with Switzerland-based Opterion Health AG for an exclusive license covering patents, know-how, and platform technology associated with OPT101, a Class 1 innovative drug for peritoneal dialysis. The agreement grants SSY rights to research, develop, manufacture, and commercialize OPT101 in mainland China until 2038, with a right of first refusal for Hong Kong, Taiwan, and Russia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68222#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68222\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68222#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health - Insight, China&#039;s Pharmaceutical Industry","description":"SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with Switzerland-based Opterion Health AG for an exclusive license covering patents, know-how, and platform technology associated with OPT101, a Class 1 innovative drug for peritoneal dialysis. The agreement grants SSY rights to research, develop, manufacture, and commercialize OPT101 in mainland China until 2038, with a right of first refusal for Hong Kong, Taiwan, and Russia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68222","og_locale":"en_US","og_type":"article","og_title":"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health","og_description":"SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with Switzerland-based Opterion Health AG for an exclusive license covering patents, know-how, and platform technology associated with OPT101, a Class 1 innovative drug for peritoneal dialysis. The agreement grants SSY rights to research, develop, manufacture, and commercialize OPT101 in mainland China until 2038, with a right of first refusal for Hong Kong, Taiwan, and Russia.","og_url":"https:\/\/flcube.com\/?p=68222","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T13:49:10+00:00","article_modified_time":"2026-06-15T13:49:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68222#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68222"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health","datePublished":"2026-06-15T13:49:10+00:00","dateModified":"2026-06-15T13:49:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68222"},"wordCount":555,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2005","Opterion Health","SSY Group"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68222#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68222","url":"https:\/\/flcube.com\/?p=68222","name":"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-15T13:49:10+00:00","dateModified":"2026-06-15T13:49:12+00:00","description":"SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with Switzerland-based Opterion Health AG for an exclusive license covering patents, know-how, and platform technology associated with OPT101, a Class 1 innovative drug for peritoneal dialysis. The agreement grants SSY rights to research, develop, manufacture, and commercialize OPT101 in mainland China until 2038, with a right of first refusal for Hong Kong, Taiwan, and Russia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68222#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68222"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68222#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68222"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68222\/revisions"}],"predecessor-version":[{"id":68228,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68222\/revisions\/68228"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}